Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 7/20 | 0.35 |
| ▸ | RBP4 | P02753 | 5/20 | 0.34 |
| ▸ | TTR | P02766 | 4/20 | 0.34 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.33 |
| ▸ | CDK2 | P24941 | 3/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL512279 | 1.00 | RET (0.35) | RETRBP4TTRCCNE1CDK2 | |
| SCHEMBL513785 | 1.00 | RET (0.35) | RETRBP4TTRCCNE1CDK2 | |
| SCHEMBL512702 | 0.92 | RET (0.35) | RETRBP4TTRCCNE1CDK2 | |
| SCHEMBL476973 | 0.92 | RET (0.35) | RETRBP4TTRCCNE1CDK2 | |
| SCHEMBL512703 | 0.92 | RET (0.35) | RETRBP4TTRCCNE1CDK2 | |
| SCHEMBL514034 | 0.90 | RBP4 (0.35) | RETRBP4TTRCCNE1CDK2 | |
| SCHEMBL512818 | 0.90 | RBP4 (0.35) | RETRBP4TTRCCNE1CDK2 | |
| SCHEMBL512315 | 0.85 | RBP4 (0.40) | RETRBP4TTRCCNE1CDK2 | |
| SCHEMBL512316 | 0.85 | RBP4 (0.40) | RETRBP4TTRCCNE1CDK2 | |
| SCHEMBL10079526 | 0.78 | CCNE1 (0.35) | RETRBP4TTRCCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492397-B2 | Aminopyridine derivatives having Aurora A selective inhibitory action | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-23 | — | — | US | claimed |
| US-8492397-B2 | Aminopyridine derivatives having Aurora A selective inhibitory action | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-23 | — | — | US | disclosed |
| US-20120029004-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | BANYU PHARMACEUTICALS CO., LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029004-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | AURKA, AURKC, AURKB | RET 1577/4885RBP4 4627/4885TTR 4855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.